0.00Open0.00Pre Close0 Volume0 Open Interest110.00Strike Price0.00Turnover128.08%IV-56.65%PremiumDec 20, 2024Expiry Date143.74Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9974Delta0.0001Gamma1.76Leverage Ratio-0.0263Theta0.0669Rho1.76Eff Leverage0.0050Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet